The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
Step inside Israeli innovation at the David and Janet Polak Visitors Center. Experience our 360° immersive movie and tech exhibition. Open to individuals and groups.
Learn MoreAs seen on nocamels.com.
An Israeli startup that uses artificial intelligence to help manage treatment courses for diabetics has received a fifth clearance from the US Food and Drug Administration (FDA) for its endo.digital platform.
The new FDA clearance allows DreaMed (opens in a new tab) to expand the scope of its recommended care plans for diabetics on a fixed regimen of insulin doses that are administered via pump or injection.
The endo.digital platform provides an automated total care plan for people with diabetes. The company says it is compatible with most devices used by diabetics to monitor their blood glucose levels and to administer insulin.
DreaMed Diabetes uses artificial intelligence to help manage treatment courses for diabetics. DreaMed Cofounder and Chief Medical R&D Officer Revital Nimri is a Technion alumna.